TECHNICAL FIELD

Generally disclosed herein are compositions, systems, and methods for the removal of molecules from a biological fluid that may elicit an undesirable physiological response that may when said fluid is administered to a subject. More specifically disclosed herein are compositions, systems, and methods for the preparation of a universal blood product.

BACKGROUND

Human plasma is a source of over 700 proteins, many of them with considerable therapeutic value such as albumin, clotting factors (Factor VIII, IX, XIII, prothrombin, fibrinogen, von Willebrandt factor), immunoglobulins (Ig), protease inhibitors, and others. Therapeutic plasma is obtained from whole blood donated by volunteers using well-established blood bank separation techniques. These techniques although effective in removal of viral and bacterial pathogens are ineffective in removal of autoantibodies and disease mediators such as inflammatory cytokines, and the like. There are many examples that plasma from one donor who is a carrier of undiagnosed and asymptomatic autoimmune disease can contaminate a large pool of plasma and expose many recipients to these disease mediators. A similar situation could exist with undiagnosed and asymptomatic blood donors who carry high levels of inflammatory cytokines and other active molecules formed in metabolic diseases.

Examination of a number of standard pools of plasma showed that a proportion contained ‘immune’ anti-A or anti-B antibodies. Anti-A antibodies are originated from the immune response towards influenza virus, whose epitopes are similar enough to be antigenic. Anti-B antibodies are reactive against antigen found on red blood cells, and may also be formed against bacterial antigens. The anti-A and anti-B antibodies are usually immunoglobulins with a molecular weights ranging from about 100 kDa to about 1000 kDa and pIs ranging from 5.5-7.4. These antibodies may under certain conditions produce undesirable clinical and hematological side-effects. The presence in plasma of Anti-A and Anti-B antibodies significantly limits the overall plasma donor pool and necessitates time consuming screening tests, complicating blood transfusions.

There exists an ongoing need for compositions and methods able to effectively produce a universal blood product.

SUMMARY

Disclosed herein is a method of preparing a universal blood product comprising obtaining a blood product wherein the blood product comprises whole blood or plasma; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size α and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; and recovering the cleansed product.

Also disclosed herein is a method of preparing a universal blood product comprising obtaining a blood product wherein the blood product comprises whole blood or plasma; contacting the blood product with (i) hydroxyapatite; (ii) a carbonaceous material comprising at least a mixture of a first carbon particle having macroporous size at and a second carbon particle having macroporous size β; and (iii) at least one support matrix chemically associated with an antigenic determinant. to form a cleansed product; wherein at least one of the hydroxyapatite, carbonaceous material and support matrix is functionalized.

